220 related articles for article (PubMed ID: 25650370)
1. Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy.
Beadle RM; Williams LK; Kuehl M; Bowater S; Abozguia K; Leyva F; Yousef Z; Wagenmakers AJ; Thies F; Horowitz J; Frenneaux MP
JACC Heart Fail; 2015 Mar; 3(3):202-11. PubMed ID: 25650370
[TBL] [Abstract][Full Text] [Related]
2. Metabolic manipulation in chronic heart failure: study protocol for a randomised controlled trial.
Beadle RM; Williams LK; Abozguia K; Patel K; Leon FL; Yousef Z; Wagenmakers A; Frenneaux MP
Trials; 2011 Jun; 12():140. PubMed ID: 21645332
[TBL] [Abstract][Full Text] [Related]
3. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy.
Abozguia K; Elliott P; McKenna W; Phan TT; Nallur-Shivu G; Ahmed I; Maher AR; Kaur K; Taylor J; Henning A; Ashrafian H; Watkins H; Frenneaux M
Circulation; 2010 Oct; 122(16):1562-9. PubMed ID: 20921440
[TBL] [Abstract][Full Text] [Related]
4. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.
Lee L; Campbell R; Scheuermann-Freestone M; Taylor R; Gunaruwan P; Williams L; Ashrafian H; Horowitz J; Fraser AG; Clarke K; Frenneaux M
Circulation; 2005 Nov; 112(21):3280-8. PubMed ID: 16301359
[TBL] [Abstract][Full Text] [Related]
5. Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure.
Bonnet D; Berger F; Jokinen E; Kantor PF; Daubeney PEF
J Am Coll Cardiol; 2017 Sep; 70(10):1262-1272. PubMed ID: 28859790
[TBL] [Abstract][Full Text] [Related]
6. Perhexiline, Cardiac Energetics, and Heart Failure: Lessons From the First Law of Thermodynamics.
Davogustto G; Taegtmeyer H
JACC Heart Fail; 2015 Aug; 3(8):659-60. PubMed ID: 26251097
[No Abstract] [Full Text] [Related]
7. Reply: Perhexiline, Cardiac Energetics, and Heart Failure: Lessons From the First Law of Thermodynamics.
Beadle RM; Frenneaux MP
JACC Heart Fail; 2015 Aug; 3(8):660. PubMed ID: 26251098
[No Abstract] [Full Text] [Related]
8. Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome.
Singh S; Beadle R; Cameron D; Rudd A; Bruce M; Jagpal B; Schwarz K; Brindley G; Mckiddie F; Lang C; Dawson D; Frenneaux M
Future Cardiol; 2014 Nov; 10(6):693-8. PubMed ID: 25495811
[TBL] [Abstract][Full Text] [Related]
9. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study.
Eichhorn EJ; Heesch CM; Barnett JH; Alvarez LG; Fass SM; Grayburn PA; Hatfield BA; Marcoux LG; Malloy CR
J Am Coll Cardiol; 1994 Nov; 24(5):1310-20. PubMed ID: 7930255
[TBL] [Abstract][Full Text] [Related]
10. Effects of surgical ventricular reconstruction and mitral complex reconstruction on cardiac oxidative metabolism and efficiency in nonischemic and ischemic dilated cardiomyopathy.
Sugiki T; Naya M; Manabe O; Wakasa S; Kubota S; Chiba S; Iwano H; Yamada S; Yoshinaga K; Tamaki N; Tsutsui H; Matsui Y
JACC Cardiovasc Imaging; 2011 Jul; 4(7):762-70. PubMed ID: 21757167
[TBL] [Abstract][Full Text] [Related]
11. Perhexiline: lessons for heart failure therapeutics.
Cappola TP
JACC Heart Fail; 2015 Mar; 3(3):212-3. PubMed ID: 25650368
[No Abstract] [Full Text] [Related]
12. I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life.
Abdel-Salam Z; Rayan M; Saleh A; Abdel-Barr MG; Hussain M; Nammas W
Cardiol J; 2015; 22(2):227-32. PubMed ID: 25179314
[TBL] [Abstract][Full Text] [Related]
13. Retained Metabolic Flexibility of the Failing Human Heart.
Watson WD; Green PG; Lewis AJM; Arvidsson P; De Maria GL; Arheden H; Heiberg E; Clarke WT; Rodgers CT; Valkovič L; Neubauer S; Herring N; Rider OJ
Circulation; 2023 Jul; 148(2):109-123. PubMed ID: 37199155
[TBL] [Abstract][Full Text] [Related]
14. Exercise training in dilated cardiomyopathy improves rest and stress cardiac function without changes in cardiac high energy phosphate metabolism.
Holloway CJ; Dass S; Suttie JJ; Rider OJ; Cox P; Cochlin LE; Jackson H; Fast AM; Johnson AW; Karamitsos TD; Neubauer S; Clarke K
Heart; 2012 Jul; 98(14):1083-90. PubMed ID: 22739638
[TBL] [Abstract][Full Text] [Related]
15. Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?
Santos-Gallego CG; Garcia-Ropero A; Mancini D; Pinney SP; Contreras JP; Fergus I; Abascal V; Moreno P; Atallah-Lajam F; Tamler R; Lala A; Sanz J; Fuster V; Badimon JJ
Cardiovasc Drugs Ther; 2019 Feb; 33(1):87-95. PubMed ID: 30675708
[TBL] [Abstract][Full Text] [Related]
16. Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients With Chronic Heart Failure and Iron Deficiency.
Charles-Edwards G; Amaral N; Sleigh A; Ayis S; Catibog N; McDonagh T; Monaghan M; Amin-Youssef G; Kemp GJ; Shah AM; Okonko DO
Circulation; 2019 May; 139(21):2386-2398. PubMed ID: 30776909
[TBL] [Abstract][Full Text] [Related]
17. Effects of exercise training on myocardial energy metabolism and ventricular function assessed by quantitative phosphorus-31 magnetic resonance spectroscopy and magnetic resonance imaging in dilated cardiomyopathy.
Beer M; Wagner D; Myers J; Sandstede J; Köstler H; Hahn D; Neubauer S; Dubach P
J Am Coll Cardiol; 2008 May; 51(19):1883-91. PubMed ID: 18466804
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial of perhexiline on regression of left ventricular hypertrophy in patients with symptomatic hypertrophic cardiomyopathy (RESOLVE-HCM trial).
Ananthakrishna R; Lee SL; Foote J; Sallustio BC; Binda G; Mangoni AA; Woodman R; Semsarian C; Horowitz JD; Selvanayagam JB
Am Heart J; 2021 Oct; 240():101-113. PubMed ID: 34175315
[TBL] [Abstract][Full Text] [Related]
19. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy.
Osterziel KJ; Strohm O; Schuler J; Friedrich M; Hänlein D; Willenbrock R; Anker SD; Poole-Wilson PA; Ranke MB; Dietz R
Lancet; 1998 Apr; 351(9111):1233-7. PubMed ID: 9643742
[TBL] [Abstract][Full Text] [Related]
20. Extracellular volume fraction assessed using cardiovascular magnetic resonance can predict improvement in left ventricular ejection fraction in patients with dilated cardiomyopathy.
Inui K; Asai K; Tachi M; Yoshinaga A; Izumi Y; Kubota Y; Murai K; Tsukada YT; Amano Y; Kumita S; Shimizu W
Heart Vessels; 2018 Oct; 33(10):1195-1203. PubMed ID: 29560528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
